Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.
Stocks · News reference
Insmed Announces Japan's Ministry Of Health, Labour And Welfare Approved BRINSUPRI For Non-Cystic Fibrosis Bronchiectasis In Patients 12 Years And Older
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Insmed announced FDA acceptance of a regulatory filing for Arikayce label expansion to treat newly diagnosed MAC lung disease patients. The FDA granted priority review with a decision expected by January 28, 2027. Arikayce sales grew 7% to $214.4 million in H1 2026, with full-year expectations of $450-470 million. The label expansion could significantly increase the addressable market from 30,000 to over 200,000 patients.
The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027
Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.